Thalassaemia - Clinical trials 

  • Clinical trials

Clinical trials for Thalassaemia

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Thalassaemia. For all clinical trials, go to clinical trials search

This list shows clinical trials for Thalassaemia

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Thalassaemia
Title Recruitment status Location
Pilot of oral Sildenafil for the treatment of Pulmonary Hypertension in Thalassaemia with comparison to controls. - Pulmonary Hypertension (PHT)Study Not Recruiting United Kingdom
A randomised, comparative, open label phase III trial on efficacy and safety of long-term treatment with ICL670 (5 to 40 mg/kg/day) in comparison with deferoxamine (DFO) (20 to 60 mg/kg/day) in ß-thalassaemia patients with transfusional haemosiderosis Not recruiting United Kingdom
Safety and Efficacy of Deferasirox in ß-thalassaemia Patients With Severe Cardiac Iron Overload Recruiting Greece
Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload Not recruiting Hungary
Evaluating the efficacy of Exjade® (deferasirox) in transfusion dependent chronic anaemias ( Myelodysplasia Syndrome, Beta-thalassaemia major patients) with chronic iron overload Not Recruiting Hungary
A randomised, comparative, open label phase III trial on efficacy and safety of long-term treatment with ICL670 (5 to 40 mg/kg/day) in comparison with deferoxamine (DFO) (20 to 60 mg/kg/day) in ß-thalassaemia patients with transfusional haemosiderosis Not recruiting Argentina
A randomised, comparative, open label phase III trial on efficacy and safety of long-term treatment with ICL670 (5 to 40 mg/kg/day) in comparison with deferoxamine (DFO) (20 to 60 mg/kg/day) in ß-thalassaemia patients with transfusional haemosiderosis Not recruiting Belgium
A randomised, comparative, open label phase III trial on efficacy and safety of long-term treatment with ICL670 (5 to 40 mg/kg/day) in comparison with deferoxamine (DFO) (20 to 60 mg/kg/day) in ß-thalassaemia patients with transfusional haemosiderosis Not recruiting Brazil
A randomised, comparative, open label phase III trial on efficacy and safety of long-term treatment with ICL670 (5 to 40 mg/kg/day) in comparison with deferoxamine (DFO) (20 to 60 mg/kg/day) in ß-thalassaemia patients with transfusional haemosiderosis Not recruiting Canada
A randomised, comparative, open label phase III trial on efficacy and safety of long-term treatment with ICL670 (5 to 40 mg/kg/day) in comparison with deferoxamine (DFO) (20 to 60 mg/kg/day) in ß-thalassaemia patients with transfusional haemosiderosis Not recruiting France
  • Link to Directgov – public services all in one place
  • The Information Standard - Certified member